AngioDynamics pairs a bullish technical breakout and a three-quarter earnings beat streak — with another print in just 10 days — against a business quality score that sits below the engine's floor and options positioning that is unusually skewed toward puts, making this a momentum-and-catalyst trade rather than a quality-driven one.
Thesis pillars
- Quality Below Floor→Stable
- Bullish Breakout Setup↓Deteriorating
- Earnings Beat Streak→Stable
- +1 more pillar — see the Why tab for full reasoning
AngioDynamics, Inc. (ANGO) Stock Analysis
Inst Constrain edge
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $15.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: Below-average business quality.
AngioDynamics designs, manufactures, and sells medical devices for cardiovascular disease and cancer treatment through two segments, Med Tech (Auryon, NanoKnife, AlphaVac, AngioVac) and Med Device (peripheral vascular, drainage, and port products). The company sells in the U.S.... Read more
Sell if holding. Engine safety override at $15.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 49d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
About AngioDynamics, Inc.
About AngioDynamics, Inc.
AngioDynamics markets its medical-device portfolio through two segments, Med Tech — anchored by the Auryon atherectomy system, NanoKnife ablation system, and the AlphaVac/AngioVac thrombectomy platforms — and Med Device, covering peripheral vascular, drainage, and port products. In December 2024, NanoKnife received expanded FDA 510(k) clearance for prostate-tissue ablation. International revenue, which fell 21% in fiscal 2025 after divesting the dialysis, BioSentry, PICC, and Midline businesses, still depends on third-party distributors for approximately 74% of sales outside the U.S.
AngioDynamics generates revenue from device and disposable sales — atherectomy catheters, thrombectomy systems, ablation generators and probes, vascular access ports, and angiographic catheters — sold in the United States primarily through a direct sales force and internationally through a mix of direct sales and third-party distributors across markets including China, Japan, Brazil, and the Middle East. The company manufactures many of its own products from two leased New York facilities in Queensbury and Glens Falls, supplemented by a supply agreement with Biomerics in Costa Rica and other third-party contract manufacturers, and is mid-transition on a restructuring plan announced in January 2024 to shift additional production to Costa Rica, Latvia, Italy, Israel, and China, expected to complete in the third quarter of fiscal 2026. Growth in higher-value platforms such as Auryon, AlphaVac, and NanoKnife depends on continued clinical-trial data generation, including the ongoing Ambition BTK study, to support physician adoption and reimbursement. AngioDynamics competes against larger, better-resourced medical-device makers including Boston Scientific and Medtronic.
Show full overview
AngioDynamics carries a litigation overhang tied to its historical port products: numerous product-liability claims previously pending in various state and federal courts have been consolidated into a single multidistrict litigation in the U.S. District Court for the Southern District of California, and the company says it cannot predict the outcome. That overhang compounds a related supply risk: the 10-K discloses dependence on single and limited-source suppliers for several key products, a risk that already interrupted production during fiscal 2022 and 2023, even as the company simultaneously shifts manufacturing from its historical Queensbury, NY base to third-party partners in Costa Rica, Latvia, Italy, Israel, and China.
See also: Healthcare · Medical Instruments & Supplies
From AngioDynamics, Inc.'s most recent 10-K filing, extracted August 9, 2026.
Recent developments
updated 2026-08-12Recent Developments — AngioDynamics, Inc.
Latest news
- NEWS 12 Health Care Stocks Moving In Wednesday's After-Market Session — benzinga Aug 12, 2026 neutral
- NEWS HC Wainwright & Co. Maintains Buy on AngioDynamics, Raises Price Target to $19 — benzinga Jul 15, 2026 positive
- NEWS Canaccord Genuity Maintains Buy on AngioDynamics, Raises Price Target to $20 — benzinga Jul 15, 2026 positive
- NEWS Full Transcript: AngioDynamics Q4 2026 Earnings Call — benzinga Jul 14, 2026 positive
- NEWS Earnings Scheduled For July 14, 2026 — benzinga Jul 14, 2026 neutral
Generated 2026-08-14T11:47:19Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle and limited source suppliers10-K Item 1A: 'We are dependent on single and limited source suppliers which subjects our business and results of operations to risks of supplier business interruptions.'
- HIGHcounterpartyinternational distributors74%10-K Item 1A: 'International distributors accounted for approximately 74% of international revenues for the fiscal year ended May 31, 2025.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Unprofitable operations — net margin -11.5%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.71: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.72. Score 5.8/10, moderate confidence.
Take-profit target: $17.00 (+8.1% upside). Prior stop was $14.72. Stop-loss: $14.72.
Concentration risk — Supplier: single and limited source suppliers; Concentration risk — Counterparty: international distributors (74.0%); Quality below floor (3.9 < 4.0).
AngioDynamics, Inc. trades at a P/E of N/A (forward -350.0). TrendMatrix value score: 7.2/10. Verdict: Sell.
10 analysts cover ANGO with a consensus score of 4.1/5. Average price target: $20.
What does AngioDynamics, Inc. do?AngioDynamics designs, manufactures, and sells medical devices for cardiovascular disease and cancer treatment through...
AngioDynamics designs, manufactures, and sells medical devices for cardiovascular disease and cancer treatment through two segments, Med Tech (Auryon, NanoKnife, AlphaVac, AngioVac) and Med Device (peripheral vascular, drainage, and port products). The company sells in the U.S. primarily through a direct sales force and internationally through direct sales and distributors, with international distributors accounting for approximately 74% of international revenue in fiscal 2025.